[HTML][HTML] Targeted therapies in non-small cell lung cancer—beyond EGFR and ALK
SI Rothschild - Cancers, 2015 - mdpi.com
Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic
paradigm shift over the past decade. Advances in our understanding of the underlying …
paradigm shift over the past decade. Advances in our understanding of the underlying …
Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK
SI Rothschild - Cancers, 2015 - search.proquest.com
Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic
paradigm shift over the past decade. Advances in our understanding of the underlying …
paradigm shift over the past decade. Advances in our understanding of the underlying …
[引用][C] Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
S Rothschild - Cancers, 2015 - cir.nii.ac.jp
Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK.
SI Rothschild - Cancers, 2015 - folia.unifr.ch
English Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic
paradigm shift over the past decade. Advances in our understanding of the underlying …
paradigm shift over the past decade. Advances in our understanding of the underlying …
Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK
SI Rothschild - Cancers, 2015 - pubmed.ncbi.nlm.nih.gov
Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic
paradigm shift over the past decade. Advances in our understanding of the underlying …
paradigm shift over the past decade. Advances in our understanding of the underlying …
[HTML][HTML] Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
SI Rothschild - Cancers, 2015 - ncbi.nlm.nih.gov
Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic
paradigm shift over the past decade. Advances in our understanding of the underlying …
paradigm shift over the past decade. Advances in our understanding of the underlying …
[PDF][PDF] Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
SI Rothschild - Citeseer
Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic
paradigm shift over the past decade. Advances in our understanding of the underlying …
paradigm shift over the past decade. Advances in our understanding of the underlying …
[PDF][PDF] Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
SI Rothschild - cyberleninka.org
Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic
paradigm shift over the past decade. Advances in our understanding of the underlying …
paradigm shift over the past decade. Advances in our understanding of the underlying …
Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK.
SI Rothschild - Cancers, 2015 - sonar.ch
English Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic
paradigm shift over the past decade. Advances in our understanding of the underlying …
paradigm shift over the past decade. Advances in our understanding of the underlying …
[PDF][PDF] Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
SI Rothschild - academia.edu
Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic
paradigm shift over the past decade. Advances in our understanding of the underlying …
paradigm shift over the past decade. Advances in our understanding of the underlying …